Parker Institute for Cancer Immunotherapy

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Parker Institute for Cancer Immunotherapy sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Parker Institute for Cancer Immunotherapy: 5 sponsored US clinical trials, none currently recruiting.

Parker Institute for Cancer Immunotherapy sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Melanoma, with 1 trials.

Upper-quartile sponsor footprint

Parker Institute for Cancer Immunotherapy sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

COMPLETED Phase 1

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
COMPLETED Phase 1

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

NCT03817125
COMPLETED Phase 2

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

NCT03651271
COMPLETED Phase 1

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

NCT03214250
COMPLETED Phase 2

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

NCT02731729

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Therapeutic Areas

Metastatic Melanoma 1
Melanoma 1

How the Parker Institute for Cancer Immunotherapy early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Metastatic Melanoma (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Parker Institute for Cancer Immunotherapy: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Parker Institute for Cancer Immunotherapy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Parker Institute for Cancer Immunotherapy4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Parker Institute for Cancer Immunotherapy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Parker Institute for Cancer Immunotherapy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Parker Institute for Cancer Immunotherapy page

5 registered trials is a research-attention snapshot, not an endorsement of Parker Institute for Cancer Immunotherapy or any single study.

  • None of Parker Institute for Cancer Immunotherapy's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Metastatic Melanoma is the condition Parker Institute for Cancer Immunotherapy studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Parker Institute for Cancer Immunotherapy pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.